94 results about "Vascular malformation" patented technology

An implantable stent-like device for treating and occluding arteriovascular malformations (AVMs), fistulas, varicose veins or the like. More particularly, this invention relates to an implant body that includes an open-cell shape-transformable polymer structure that provides stress-free means for occluding an AVM without applying additional pressures an any distended walls of the AVM. In one embodiment, the shape-transformable polymer is a shape memory polymer implant body that self-deploys from a temporary shape to a memory shape. In another embodiment, the shape memory polymer structure is capable of a temporary compacted shape for carrying about the struts of an expandable stent for self-deployment to occlude an aneurysm.

The present invention provides systems and methods for occluding and/or embolizing a cavity within a patient by delivering a prepolymer material into or onto a cavity and forming an expanding foam within the cavity. The inventions methods are applicable to occluding a variety of cavities, including blood vessels, aneurysms, left arterial appendages, vascular malformations and the like.

A system for treating a wide-neck aneurysm comprising a mesh-like sleeve fabricated from a class of polymer filaments that carry conductive particles therein to provide the filaments with a specified resistivity. The releasable mesh-like sleeve is introduced to the site of a targeted vascular malformation by the working end of a catheter that carries an electrode arrangement at its distal terminus. The system further provides an electrical source and controller (i) that modulates power delivery to the polymer matrix which can then fuse the sleeve to the wall of a blood vessel to span across the vascular malformation.

Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin(TM), interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a functional tissue producing the desired biologically active agent. Implantation may be ectopic or in some cases orthotopic. Representative cell types include tissue specific cells, progenitor cells, and stem cells. Matrices can be formed of synthetic or natural materials, by chemical coupling at the time of implantation, using standard techniques for formation of fibrous matrices from polymeric fibers, and using micromachining or microfabrication techniques. These devices and strategies are used as delivery systems via standard or minimally invasive implantation techniques for any number of parenterally deliverable recombinant proteins, particularly those that are difficult to produce in large amounts and/or active forms using conventional methods of purification, for the treatment of a variety of conditions that produce abnormal growth, including treatment of malignant and benign neoplasias, vascular malformations (hemangiomas), inflammatory conditions, keloid formation, abdominal or plural adhesions, endometriosis, congenital or endocrine abnormalities, and other conditions that can produce abnormal growth such as infection. Efficacy of treatment with the therapeutic biologicals is detected by determining specific criteria, for example, cessation of cell proliferation, regression of abnormal tissue, or cell death, or expression of genes or proteins reflecting the above.

A system for treating a wide-neck aneurysm comprising a mesh-like sleeve fabricated from a class of polymer filaments that carry conductive particles therein to provide the filaments with a specified resistivity. The releasable mesh-like sleeve is introduced to the site of a targeted vascular malformation by the working end of a catheter that carries an electrode arrangement at its distal terminus. The system further provides an electrical source and controller (i) that modulates power delivery to the polymer matrix which can then fuse the sleeve to the wall of a blood vessel to span across the vascular malformation.

An artery, vein, aneurysms vascular malformation or arterial fistula is occluded through endovascular occlusion by the endovascular insertion of a platinum wire and/or tip into the vascular cavity. The vascular cavity is packed with the tip to obstruct blood flow or access of blood in the cavity such that the blood clots in the cavity and an occlusion if formed. The tip may be elongate and flexible so that it packs the cavity by being folded upon itself a multiple number of times, or may pack the cavity by virtue of a filamentary or fuzzy structure of the tip. The tip is then separated from the wire mechanically or by electrolytic separation of the tip from the wire. The wire and the microcatheter are thereafter removed leaving the tip embedded in the thrombus formed within the vascular cavity. Movement of wire in the microcatheter is more easily tracked by providing a radioopaque proximal marker on the microcatheter and a corresponding indicator marker on the wire. Electrothrombosis is facilitate by placing the ground electrode on the distal end of the microcatheter and flowing current between the microcatheter electrode and the tip.

REEAXMINATION RESULTS The questions raised in reexamination request 90/007,231, filed Oct. 4, 2004 have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e), for ex parte reexaminations, or the reexamination certificate required by 35 U.S.C. 316 as provided in 37 CFR 1.99(e) for inter partes reexaminations.

An intralumenal implant material, which comprises, a polymer having a sol-gel transition temperature in an aqueous solution thereof, shows a substantial water-insolubility at a temperature higher than the sol-gel transition temperature, and shows a thermo-reversible water-solubility at a temperature lower than the sol-gel transition temperature. Such an intralumenal implant is capable to be endovascularly or percutaneuosly delivered into a vascular lumen in a liquid state at the temperature lower than the sol-gel transition temperature, is capable to be instantly converted into a gel state in the vascular lumen at the blood temperature higher than the sol-gel transition temperature and is capable of occluding aneurysms, vascular tumors or vascular malformation. Such intralumenal implant material shows excellent biocompatibility and mechanical matching for the vascular tissue and the surrounding tissue because it is a highly water-containing hydrogel. In addition, biologically active substances for promoting a prompt neo-endothelium formation and/or endothelialization can be easily incorporated into such an intralumenal implant material.

The invention is also directed to a device for treating an aneurysm which has a cover covering the neck of the aneurysm and a lateral portion extending into the aneurysm. The invention is also directed to a cover which is used to cover the neck of the aneurysm thereby isolating the aneurysm from the parental vessel.

Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain Rho kinase inhibitors.

The invention discloses a magnetic resonance imaging detectable in-situ liquid crystal precursor embolism composition which comprises the following components: an MRI water-soluble or water-insoluble contrast medium, a liquid crystal material, a physiological acceptable water-soluble organic solvent and water. The following components can be added according to the treatment goal and the clinical demand: an X ray-impermeable water-soluble or water-insoluble contrast medium and/or drugs. The MRI detectable liquid embolism composition disclosed by the invention has the characteristics of low viscosity, no toxicity, low cost and fast curing, can be injected, and is mainly used in local embolism treatment and relevant imageological examination of tumors, vascular malformation and hemostasis.

The invention discloses DDX24 gene mutation and an application thereof. The DDX24 gene SNP (single-nucleotide polymorphism) mutation comprises Glu271Lys, Lys11Glu and Arg436His. The DDX24 gene mutation Glu271Lys, Lys11Glu or Arg436His is remarkably correlated with development of vessels. By means of interference to DDX24, cell migration and vascular formation can be promoted, and occurrence of vascular malformation is reminded. The occurrence condition of the vascular malformation of a human body can be effectively predicted by detecting SNP loci of DDX24, the DDX24 gene mutation can be used for screening genetic defects and is beneficial to true judgment of types of abnormal diseases of the vessels, misdiagnosis is reduced, and specific treatment is convenient.

The invention relates to a balloon microcatheter with a detachable tip. The balloon microcatheter comprises a microcatheter body, one end of the microcatheter body is communicated with a catheter base, and the other end of the microcatheter body is connected with the detachable microcatheter tip; a cannula is coaxially arranged outside the microcatheter body, and the two ends of the cannula are communicated with the catheter base and an inflatable balloon on the microcatheter body respectively. The balloon microcatheter has the advantages that the curative embolization rate of minimally invasive intervention treatment of cerebrovascular malformation can be increased, complications caused when a liquid emboliaztion agent flows back and hemorrhage related to incomplete embolization can be reduced, the treatment process is simplified, and the economic burden is relieved.

The invention discloses a magnetic resonance imaging (MRI) detectable liquid embolism composition which comprises the following components: an MRI water-soluble or water-insoluble contrast medium, an embolism material, a physiological acceptable water-soluble organic solvent and water. The following components can be added according to the treatment goal and the clinical demand: an X ray-impermeable water-soluble or water-insoluble contrast medium and/or drugs. The MRI detectable liquid embolism composition disclosed by the invention has the characteristics of low viscosity, no toxicity, low cost and fast curing, can be injected, and is mainly used in local embolism treatment and relevant imageological examination of tumors, vascular malformation and hemostasis.

The invention relates to a detachable micro-catheter with double-coating at the head end. The detachable micro-catheter with double-coating at the head end comprises a microcatheter body, a catheter base connected at one end of the microcatheter body, and a detachable microcatheter head connected at the other end of the microcatheter body, the outer surface of the microcatheter head is coated withan expandable inner layer coating, and the inner layer coating is also tightly sealed and tightly coated with a variable loose outer layer coating. The detachable micro-catheter with double-coating at the head end has the beneficial effects that the curative embolization rate of the minimally invasive interventional treatment of the cerebral vascular malformation can be improved, the complications caused by the return flow of the liquid embolism agent and the bleeding due to embolism are reduced, the treatment process is simplified, and the economic burden is reduced.

The invention discloses a pingyangmycin polyethylene glycol (PEG)-polycaprolactone (PCL)-polyethylene glycol (PEG) temperature-sensitive slow-release gel, as well as a preparation method and the application of the gel. The Pingyangmycin PEG-PCL-PEG temperature-sensitive slow-release gel mainly consists of two parts comprising PEG (polyethylene glycol)-PCL (polycaprolactone)-PEG (polyethylene glycol) co-polymer and Pingyangmycin, is liquid at room temperature, and is solid gel under the in vivo 37 DEG C condition; the gel system has significant slow-release effect, thereby having functions in prolonging the half-life period and the acting time of the Pingyangmycin, reducing drug concentration in plasma, and reducing systemic toxic and side effects. The gel can be formed in situ after the medicine is injected in a high-flow-speed vessel, and then location embolism is realized, and so as to realize the, and muscularization and closing of muscle is caused, so that the sclerotherapy and the interventional therapy are combined effectively, the gel has excellent biocompatibility and degradability, is beneficial for treating hemangiomas, vascular malformations and cancers, particularly, a new selection is provided to the treatment of the vein malformation and partial malformation of cancers.

The present disclosure relates to methods of treating a vascular malformation in a subject expressing a gain-of-function mutation in a PIK3CA gene comprising administering, to the subject, an effective amount of an agent that inhibits phosphoinositide 3-kinase (“PI3K”).

The invention discloses a compound for treating vascular malformation. The inventor researches and discovers that a CysLTR1 antagonist can up-regulate expression in a vascular smooth muscle cell DDX24, and the CysLTR1 antagonist has a certain treating or improvement effect on the vascular malformation.

Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.